Provided By GlobeNewswire
Last update: Nov 12, 2025
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer.
Read more at globenewswire.comNASDAQ:LBRX (11/26/2025, 4:30:02 PM)
16.53
+0.33 (+2.04%)
Find more stocks in the Stock Screener


